12,372 trials
Schizophrenia · Psychotic Disorders
Primary: Part-2 (Disease Progression): Time to First Treatment Failure — NA; NA days
Acetabular Fractures
Primary: Allogenic Blood Transfusion Rates — 21; 13 Participants
COPD
Primary: Ventilation Distribution as Measured by Ventilation Defect+Low Percent — 57.8; 52.5 percentage of total ventilation — p=0.006
Post Partum Hemorrhage · Fibrinolysis; Hemorrhage · Blood Loss
Primary: Blood Volume Loss — 2274; 2407 milliliters
Myelodysplastic Syndrome · Leukemia · Acute Myeloid Leukemia
Primary: Treatment-related Mortality (TRM) — 3; 3; 7; 3 Percentage of Participants — p=0.9
Rheumatoid Arthritis
Primary: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12 — 66.0; 57.5; 31.1 percentage of…
Rheumatoid Arthritis
Primary: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 24 — 81.0; 80.2; 78.1; 71.4 percentage of…
Pneumococcal Infections
Primary: Percentage of Participants With Solicited Injection-site Adverse Events Following V114 or Prevnar 13™ — 15.1; 14.0; 75.8; 68.8 Percentage of Participants
Atopic Dermatitis
Primary: Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16 — 98; 33 Participants — p=0.015
Leukemia, Myeloid, Acute
Primary: Number of Participants With a Complete Response (CR) — 79; 71 Participants — p=0.482
Impaired Glucose Tolerance
Primary: Change 2-hour Plasma Glucose (During Oral Glucose Tolerance Test). — 9.27; 9.11; 7.28; 8.32 mmol/L — p=0.0028
Eosinophilic Esophagitis (EoE)
Primary: Proportion of Participants Who Had Relapse During the Entire Week 36 Period — 0.43; 0.24 proportion of participants — p=0.131
B-Cell Non Hodgkin Lymphoma
Primary: Phase 2: Percentage of Participants Who Achieved Complete Metabolic Response (CMR) — 22.0 Percentage of participants
Diabetic Foot Ulcers
Primary: Biopsies — 2.46; 2.64; 2.56; 2.07 UI/dL
Portopulmonary Hypertension
Primary: Change in Pulmonary Vascular Resistance — 7.1 percent difference from baseline